CBOE Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction SBS Q1 2026 Earnings Modest EPS Beat Amidst Operational Efficiency Gains Kiora Pharmaceuticals Q1 2026 Earnings EPS Beat Masks Continued PreRevenue Status as Stock Slips GT Biopharma Q1 2026 Earnings Wider Loss and No Revenue as Pipeline Progress Remains Uncertain HRTG Q1 2026 Earnings EPS Misses Estimates as Underwriting Pressures Persist VRM Q3 2025 Earnings Deepening Losses Amid No Revenue Disclosure